Purpose: The aim of this study was to compare dynamic thiol/disulfide homeostatic status in acute central serous chorioretinopathy (CSCR) patients by using a novel and automated assay determining dynamic thiol/disulfide homeostasis.
Methods: Fifty-one patients with acute CSCR (study group) and 65 healthy individuals (control group) were enrolled in this study. Diagnosis of acute CSCR was made clinically and using spectral-domain RTVue OCT (optical coherence tomography) (Optovue, Fremont, CA). Fluorescein angiography confirmed the diagnosis of acute CSCR in all subjects. Total thiol, native thiol, disulfide amount, and native thiol/disulfide ratio (TDR) were calculated in the blood samples.
Results: Mean total thiol, native thiol, and native TDR values were lower in patients with acute CSCR (364.2 ± 14.1, 326.4 ± 13.2, 17.14 ± 1.9, respectively) than in healthy eyes (441.2 ± 16.3, 398.5 ± 16.4, 22.70 ± 2.15, respectively; mean total thiol, p = 0.017; native thiol, p = 0.011; native TDR, p = 0.031).
Conclusions: Total thiol, native thiol, and native TDR were significantly lower statistically in patients with acute CSCR when compared with healthy controls.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10792-017-0444-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Micropulse Laser Therapy in Central Serous Chorioretinopathy.
Clin Pract
November 2024
Doctoral School of Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.
: Central serous chorioretinopathy (CSCR) is a retinal condition characterized by the accumulation of subretinal fluid, often linked to elevated levels of endogenous corticosteroids and stress-related hormones, which can lead to visual disturbances. This connection may explain the association of CSCR with high stress levels and the use of corticosteroid medications. Although many cases resolve spontaneously, persistent or severe instances may require intervention.
View Article and Find Full Text PDFEffect of Eplerenone Treatment in Patients with Central Serous Retinopathy: A Double-Blind Randomized Clinical Trial.
J Curr Ophthalmol
October 2024
Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Purpose: To evaluate the efficacy of eplerenone in central serous chorioretinopathy (CSCR) patients in a clinical trial design.
Methods: In this double-blind clinical trial, naive acute. CSCR patients were divided into two groups: treatment with eplerenone 25 mg daily in the 1 week followed by 50 mg for the next 3 weeks and placebo group.
Therapies for Central Serous Chorioretinopathy: A Report by the American Academy of Ophthalmology.
Ophthalmology
October 2024
Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia; Department of Ophthalmology, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska.
Purpose: To assess the safety and efficacy of the multiple therapeutic modalities for the treatment of central serous chorioretinopathy (CSCR).
Methods: A literature search of English-language studies in the PubMed database with no date restrictions was last conducted in May 2024. The combined searches yielded 612 citations, 31 of which were selected for full-text review and for inclusion in this assessment.
Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.
Ann Hematol
October 2024
Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, CA, USA.
Outcomes for patients with myeloid blast phase chronic myeloid leukemia (CML-MBP) are dismal, and no preferred chemotherapy regimen has been identified. Recent studies have suggested a higher response rate with administration of timed-sequenced regimens (TSR) (purine analog, high-dose cytarabine, anthracycline) in high-risk acute myeloid leukemia patients. We retrospectively evaluated outcomes of newly diagnosed CML-MBP patients consecutively treated at our institution with a TSR or standard-dose cytarabine and an anthracycline ("7 + 3") combined with a tyrosine-kinase inhibitor (TKI) between 2011 and 2023.
View Article and Find Full Text PDFImportance of OCT-derived biomarkers for the recurrence of central serous chorioretinopathy using statistics and predictive modelling.
Sci Rep
October 2024
Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Avenue de France 15, 1001, Lausanne, Switzerland.
Article Synopsis
- * The study analyzed 5211 OCT scans from 344 eyes of 255 patients with CSCR, identifying 178 recurrent and 109 non-recurrent cases, using advanced AI techniques to extract relevant parameters.
- * Nine predictive biomarkers for CSCR recurrence were found, including age, various fluid types, and specific retinal layer thicknesses, which could enhance automatic detection and improve clinical outcomes in the future.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!